IDE892

Phase 1Small molecule

IIDEAYA Biosciences

IDE892 is one of 2 small molecule programs targeting NSCLC Adenocarcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NSCLC AdenocarcinomaRecruiting

NSCLC AdenocarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in NSCLC Adenocarcinoma

#DrugCompanyPhaseTrials

IDE892

IIDEAYA Biosciences

Phase 1

1 2

IDE397

IIDEAYA Biosciences

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

NSCLC Adenocarcinoma

NCT07277413

Clinical

Trials by Indication[1]

NSCLC Adenocarcinoma1 trial

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors

Recruiting·IIDEAYA Biosciences·Phase 1·NCT07277413·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IDE892. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IDE892 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IDE892. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IDEAYA Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IIDEAYA Biosciences

IDE892

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

NSCLC Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News